LEBSA, together with Leitat, leads the PHARO project, a pioneering circular economy initiative in the pharmaceutical industry based on water regeneration
The project aims to optimize the production processes of the industry and focuses on (…)
Latest posts
Moments to Remember: LEBSA’s Heartwarming Christmas Dinner 2023
Celebrating unforgettable moments at LEBSA! This year, we immersed ourselves in the holiday spirit (…)
Lebsa shareholders meeting: tradition and innovation unite to take the company to new heights
Reliving strategic moment from the latest Lebsa Board of shareholders meeting! In late October, (…)
Lebsa and Selectchemie Join Forces at CPHI Barcelona to Drive Innovation in the Pharmaceutical Industry
At the recent internationally renowned event, CPHI Barcelona, the pharmaceutical industry gathered at Fira (…)
Octenidine Dihydrochloride API: The Challenge for Lebsa in 2023
A couple of years ago, Lebsa challenged its R&D department to develop a new (…)
Renewed Gold EcoVadis Medal Award 2022
Awards and medals granted to individuals and companies are meant to celebrate success in (…)
What Is Coming Next?
After two years of pandemic, this 2022, events and congresses are back and at (…)
Presenting “Entenent LEBSA”: our origins, values and philosophy
On Friday, 29th of April, during the commemorative event for Lebsa’s 70th anniversary, the (…)
EDQM grants the CEP to Mianserin Hydrochloride API
One of the critical values of Lebsa is to provide regulatory support and keep (…)
Lebsa celebrates 70 years
Since Dr. Josep Maria Espinós founded Lebsa in 1951, we have served the pharmaceutical (…)
API Synthesis in Flow: Benefits of Micro to the Plant
Over the last two decades, continuous flow chemistry has received intense interest and development (…)
Process Safety as a differentiating key factor
The Chemical industry has always been considered a focus of concern for the general (…)
Mianserin Hydrochloride, a new API coming to Lebsa portfolio
In LEBSA, we’re happy to introduce a new API coming to our portfolio: Mianserin (…)
Mianserin in the treatment of depression and insomnia
The public health emergency triggered by COVID-19 is not only a matter of respiratory (…)
Nitrosamines New EMA Guidelines
Nitrosamines are classified as probable human carcinogens (substances that could cause cancer) on the (…)
EDQM grants the CEP to our API Dequalinium Chloride
In LEBSA, we are proud to report the recent updates about our products and (…)
14th Mediterranean Congress of Chemical Engineering
In our current state of pandemics, everything has changed, and we’ve been searching for (…)
Implementing LEAN Methodology will benefit efficiency, production, time to market and customer satisfaction
Along with SGS, we implemented at LEBSA one of the most exciting projects, starting (…)
LEBSA bets on R&D in order to achieve better strategic alliances
At LEBSA, we’re not falling behind in developing strategic alliances and investments to maximize (…)
How LEBSA values help build more profitable alliances?
At LEBSA, we aim to create solid, trusted and long-term relationships with our clients in order to (…)
New LEBSA Facilities With Leading Equipment: Exceeding Client Expectations
At LEBSA, we are always looking forward – and thinking about how we can (…)
Working from home: How LEBSA faces the new situation through innovation
Due to the COVID-19 coronavirus pandemic, many countries throughout Europe are still under lockdown (…)